Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 20/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 20/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400677 | 1.00 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2558097 | 0.90 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2562218 | 0.89 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL14071518 | 0.86 | HIF1A (0.76) | HIF1AEPAS1EP300 | |
| SCHEMBL2564166 | 0.85 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2565162 | 0.84 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2562044 | 0.84 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2560066 | 0.83 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2562559 | 0.82 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL14916669 | 0.81 | HIF1A (1.00) | HIF1AEPAS1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071795-B2 | Hypoxia inducible factor (Hif); for modulating mRNA translation within cells; prevents excessive vascularization | EMORY UNIVERSITY (US) | 2011-12-06 | — | — | US | claimed |
| US-20260078132-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | ONCOSPHERIX INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4587442-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | ONCOSPHERIX INC. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250074989-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | METANOIA BIO INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20240279660-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240269124-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240269111-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240262916-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-11976279-B2 | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors | EMORY UNIVERSITY (US) | 2024-05-07 | — | — | US | disclosed |
| EP-4340836-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20190112603-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2019-04-18 | — | — | US | disclosed |
| US-9381260-B2 | Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381260-B2 | Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381260-B2 | Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-9062072-B2 | Inhibitors of HIF and angiogenesis | EMORY UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130164218-A1 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS | EMORY UNIVERSITY (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164218-A1 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS | EMORY UNIVERSITY (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164218-A1 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS | EMORY UNIVERSITY (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011133659-A2 | INHIBITORS OF HIF AND ANGIOGENESIS | EMORY UNIVERSITY (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885EPAS1 16/4885EP300 1698/4885 |
| US-20130164218-A1 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS | HIF1A, HIF1AN, HYOU1 | HIF1A 1/4885EPAS1 28/4885EP300 505/4885 |
| US-20260078132-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | VHL, HIF1AN, HIF1A | HIF1A 3/4885EPAS1 83/4885EP300 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.